title: [What are the pharmacological costs of a well-controlled diabetic?].
abstract: OBJECTIVE
  To evaluate the cost of glucose lowering treatment (GLT) in our diabetic patients (DP).
  
  
  METHODS
  Cross-sectional descriptive study.
  
  
  METHODS
  Urban primary health care centre.
  
  
  METHODS
  Random sample of 294 DP with HPT.
  
  
  METHODS
  Principal variable: annual cost of GLT. Secondary Variables: age, sex, type of diabetes (DM), prescribing doctor, level of control, number of glucose lowering drugs, cardiovascular risk factors and complications.
  
  
  RESULTS
  A total of 294 diabetic patients were included, with a mean age 71.7+/-13.3 years; 52.7% women; 93.2% DM2; Annual cost of GLT: 82.979 €,(281.9 €/patient/year). General practitioner (GP) originated 32.3% of the treatments (17.7% of the costs). Annual average expenditure was significantly higher in DM1 patients, patients on treatment with triple therapy and patients controlled by an endocrinologist in a reference hospital. In the multiple linear regression the variables that explained the variation in the cost were the type of Diabetes mellitus (P<0.0001), prescription by hospital endocrinologist (p=0,002), number of glucose lowering drugs(P<0.0001), diabetic retinopathy(P: 0.019) and chronic renal failure (P: 0.027). These variables explained 44.5% of the annual cost variation of the GLT (R(2):0.445).
  
  
  CONCLUSIONS
  There is a wide variation in the costs arising from GLT of our diabetic patients. We conclude, it is essential to improve coordination between levels of care, encourage the design and use of clinical guidelines to achieve more efficient control of our patients.
authors.affiliation: ABS Sagrada Família, CAP Sagrada Família, Consorci Sanitari Integral, Barcelona, Spain. gemma.ferriz@sanitatintegral.org
authors.forename: Gemma
authors.initials: G
authors.lastname: Férriz Villanueva
authors.forename: Marta
authors.initials: M
authors.lastname: Rojas Blanc
authors.forename: Natàlia
authors.initials: N
authors.lastname: Riera Nadal
authors.forename: Clara
authors.initials: C
authors.lastname: Riera Nadal
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Fernández Martínez
authors.forename: Alba
authors.initials: A
authors.lastname: Aguado Jodar
mesh_terms: D000368:Aged; D003365:Costs and Cost Analysis; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000191:economics*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents